GLP-1 Medications for Prediabetes: Can They Prevent Type 2 Diabetes?
GLP-1 medications for prediabetes reversed high blood sugar in 81–84% of patients and cut type 2 diabetes risk by 94% in trials. Here's what the evidence shows.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on July 1, 2026
Our medical review process ensures clinical accuracy and patient safety.
Roughly 98 million American adults have prediabetes, and about 8 in 10 do not know it. Left untreated, a large share will progress to type 2 diabetes within a decade. That is the exact window where GLP-1 medications for prediabetes are now reshaping the conversation: drugs approved for obesity are turning out to be among the most powerful diabetes-prevention tools ever studied, pushing most treated patients back to normal blood sugar and slashing progression rates in multi-year trials. The question is no longer whether they work, but who should use them and for how long.
Evidence: "Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07)." — Jastreboff AM, et al. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2410819
How Prediabetes Turns Into Type 2 Diabetes
Prediabetes is defined by blood sugar that sits above normal but below the diabetes threshold — an HbA1c of 5.7–6.4%, a fasting glucose of 100–125 mg/dL, or a two-hour glucose of 140–199 mg/dL on an oral glucose tolerance test. Underneath those numbers, two problems are usually building at once: the body's cells respond less to insulin (insulin resistance), and the pancreatic beta cells that make insulin are slowly wearing out trying to compensate.
Excess body fat, especially visceral and liver fat, drives both processes. This is why weight is the lever that matters most. When people with prediabetes lose meaningful weight, insulin sensitivity improves and beta cells get a reprieve — sometimes enough to return glucose to the normal range before permanent damage is done. GLP-1 and dual-agonist medications act on this lever directly by curbing appetite and food intake, and they add a glucose-lowering effect of their own by enhancing insulin secretion when blood sugar is high and slowing gastric emptying.
What the Trials Show: Reversing Prediabetes
The evidence here is unusually strong because prediabetes was measured as a secondary or primary outcome across the major obesity trials, and one large study was designed specifically for people with prediabetes.
Semaglutide: The STEP Program and STEP 10
A pooled analysis of the STEP 1, 3, and 4 trials tracked 3,375 adults with overweight or obesity treated with once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Among participants who started with prediabetes, far more reached normal blood sugar on the drug.
Evidence: "A greater proportion of participants with prediabetes at baseline had normoglycemia at week 68 with semaglutide 2.4 mg versus placebo (84.1% vs 47.8%)." — Perreault L, et al. Diabetes Care. 2022;45(10):2396–2405. DOI: 10.2337/dc21-1785
STEP 10 then tested the drug in a population selected entirely for prediabetes: 207 adults with obesity and prediabetes were randomized 2-to-1 to semaglutide 2.4 mg or placebo for 52 weeks. Reversion to normoglycemia was a primary endpoint, and the gap was dramatic — 81% of the semaglutide group versus 14% on placebo (odds ratio 19.8, P<0.0001), alongside greater weight loss.
Evidence: "Semaglutide 2·4 mg provided superior reduction in bodyweight and reversion to normoglycaemia versus placebo in participants with obesity and prediabetes." — McGowan BM, et al. Lancet Diabetes Endocrinol. 2024. DOI: 10.1016/S2213-8587(24)00182-7
Tirzepatide: Three Years of Diabetes Prevention
The most compelling prevention data come from the extended SURMOUNT-1 trial, which followed adults with obesity and prediabetes for 176 weeks — three years — on tirzepatide (5, 10, or 15 mg weekly) or placebo. This was long enough to measure actual progression to diabetes, not just glucose changes.
The results were striking: 98.7% of tirzepatide-treated participants remained diabetes-free over three years. Only 1.3% developed type 2 diabetes versus 13.3% on placebo, a 94% reduction in risk (hazard ratio 0.07). Weight loss was sustained at −12.3%, −18.7%, and −19.7% across the three doses, compared with −1.3% on placebo. A mediation analysis suggested roughly half of the diabetes-prevention benefit tracked with weight loss, implying the drug also protects glucose metabolism through mechanisms beyond the scale — a pattern echoed in the broader debate over how much of GLP-1 benefit is weight-dependent (see our comparison of tirzepatide vs semaglutide).
Head-to-Head on Prediabetes Outcomes
| Trial | Drug | Population | Duration | Key prediabetes result |
|---|---|---|---|---|
| STEP 1/3/4 (pooled) | Semaglutide 2.4 mg | Overweight/obesity | 68 weeks | 84.1% vs 47.8% reverted to normoglycemia |
| STEP 10 | Semaglutide 2.4 mg | Obesity + prediabetes | 52 weeks | 81% vs 14% reverted to normoglycemia |
| SURMOUNT-1 (extended) | Tirzepatide 5–15 mg | Obesity + prediabetes | 176 weeks | 1.3% vs 13.3% developed diabetes (94% risk reduction) |
GLP-1 Drugs vs. the Old Standard: Lifestyle and Metformin
For two decades, diabetes prevention meant one thing: the landmark Diabetes Prevention Program (DPP). That trial randomized 3,234 high-risk adults to intensive lifestyle change, metformin, or placebo.
Evidence: "The lifestyle intervention reduced the incidence of diabetes by 58 percent and metformin by 31 percent, as compared with placebo." — Knowler WC, et al. N Engl J Med. 2002;346(6):393–403. DOI: 10.1056/NEJMoa012512
Those numbers were a milestone, and lifestyle change remains first-line care. But the contrast with newer agents is stark: a 58% relative reduction from intensive lifestyle coaching versus a 94% reduction from tirzepatide over a longer follow-up. Metformin, still the most-prescribed off-label prevention drug, delivered about 31%. The trade-off is real — lifestyle and metformin are inexpensive, well understood, and free of injection burden, while GLP-1 drugs are costly and their benefit depends on continued use.
Beyond Glucose: Cardiovascular Protection
Prediabetes is not only a diabetes risk factor; it independently raises the odds of heart attack and stroke. This is where GLP-1 therapy adds a second layer of value. In SELECT, semaglutide 2.4 mg was tested in adults with overweight or obesity and established cardiovascular disease but without diabetes — a group heavily populated by people with prediabetes.
Evidence: "Semaglutide reduced the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 20% among patients with overweight or obesity and preexisting cardiovascular disease." — Lincoff AM, et al. N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563
For a patient with prediabetes and cardiovascular risk, that means a single therapy addressing weight, glucose, and cardiac events at once — a combination lifestyle and metformin cannot match. We cover the mechanisms in depth in our guide to GLP-1 cardiovascular benefits.
The Durability Problem: What Happens When You Stop
The catch is that these effects are maintenance-dependent. The STEP 1 extension followed participants after treatment stopped. At week 68 on semaglutide, 93.6% with baseline prediabetes had normoglycemia versus 41.5% on placebo — but a year after discontinuation, that advantage largely eroded, with normoglycemia maintained in only 43.3% versus 34.0%. Weight regain paralleled glucose regain, with participants recovering about two-thirds of the weight they had lost.
The practical reading: GLP-1 medications reverse prediabetes while they are taken, but stopping abruptly tends to return glucose toward baseline. This mirrors what happens with the underlying condition itself — like blood pressure medication, these drugs manage a chronic process rather than curing it. Patients and clinicians should plan for the long term or pair the medication with durable lifestyle changes to hold gains after any taper.
Should GLP-1 Medications for Prediabetes Become Standard Care?
As of mid-2026, no GLP-1 drug carries a specific regulatory indication for prediabetes; prescribing rests on the approved obesity indication, which most people with prediabetes and a qualifying BMI already meet. Cost, insurance coverage, and access remain the biggest barriers, and treating tens of millions of people with prediabetes indefinitely raises real questions about affordability and prioritization.
A reasonable framework, consistent with current expert commentary, targets those at highest risk first:
| Best candidates | Weaker fit |
|---|---|
| Obesity (BMI ≥30) plus prediabetes | Prediabetes with normal weight |
| Prior gestational diabetes or strong family history | Low absolute progression risk |
| Established cardiovascular disease | Cost or access barriers unresolved |
| Failed to reverse prediabetes with lifestyle alone | Able to reach goals with diet and exercise |
Evidence: The magnitude of glycemic and weight benefits seen with GLP-1 receptor agonists in people with prediabetes raises the question of whether prediabetes should become a formal treatment indication for this drug class. — Apovian CM. Int J Obes. 2025. DOI: 10.1038/s41366-025-01930-2
For patients who progress from prediabetes to overt diabetes, the same drug classes remain central to management — and can even drive type 2 diabetes remission in some people.
Key Takeaways
- GLP-1 and dual-agonist medications reverse prediabetes in the large majority of treated patients — 81–84% reached normoglycemia on semaglutide 2.4 mg.
- Over three years, tirzepatide cut progression to type 2 diabetes by 94% in adults with obesity and prediabetes.
- These results outperform the historical standards of intensive lifestyle change (58%) and metformin (31%), though those remain valuable, cheaper first-line options.
- Benefits are maintenance-dependent: stopping the drug tends to bring back weight and elevated glucose, so treatment should be planned as long-term.
- The strongest candidates are people with obesity plus prediabetes, especially those with cardiovascular risk or a history of gestational diabetes, who have not reversed prediabetes through lifestyle alone.
Prediabetes is a warning, not a verdict. The evidence now shows it is one of the most reversible stages in the path to type 2 diabetes — and GLP-1 medications have become a decisive tool for turning that warning around, provided treatment is matched to the right patients and sustained over time.
References
- Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2410819
- Perreault L, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022;45(10):2396–2405. DOI: 10.2337/dc21-1785
- McGowan BM, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024. DOI: 10.1016/S2213-8587(24)00182-7
- Knowler WC, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393–403. DOI: 10.1056/NEJMoa012512
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
- Apovian CM. Prediabetes: a new indication for GLP-1s? Int J Obes. 2025. DOI: 10.1038/s41366-025-01930-2
Last updated: 2026-07-01 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.